| *Nº: WO2018185346A1 PHARMACEUTICAL COMPOSITION FOR TREATING INFECTIOUS DISEASES<br>The invention relates to a pharmaceutical composition for systemic, particularly parenteral treatment of infectious diseases, based on an aqueous, sterile and pyrogen-free solution of chlorine dioxide, which contains 5 to 1000 mg/l (ppm) dissolved chlorine dioxide (CI02) and preferably 3 to 10 g/l of an ionic tonicity regulator, optionally in combination with a non-ionic tonicity regulator. The composition additionally preferably contains a pH regulator, particularly a pH buffer system, adjusted to pH 7.3-7.5, and can furthermore contain DMSO or MSM. In the ready-to-use state, the composition is free of chlorate ions, hydrochloric acid and gaseous chlorine, or contains said components in a concentration of 1 mg/L (1 ppm) at maximum each. | | *Nº: WO2018185346A1 PHARMACEUTICAL COMPOSITION FOR TREATING INFECTIOUS DISEASES<br>The invention relates to a pharmaceutical composition for systemic, particularly parenteral treatment of infectious diseases, based on an aqueous, sterile and pyrogen-free solution of chlorine dioxide, which contains 5 to 1000 mg/l (ppm) dissolved chlorine dioxide (CI02) and preferably 3 to 10 g/l of an ionic tonicity regulator, optionally in combination with a non-ionic tonicity regulator. The composition additionally preferably contains a pH regulator, particularly a pH buffer system, adjusted to pH 7.3-7.5, and can furthermore contain DMSO or MSM. In the ready-to-use state, the composition is free of chlorate ions, hydrochloric acid and gaseous chlorine, or contains said components in a concentration of 1 mg/L (1 ppm) at maximum each. |
− | *WO2018185347A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INTERNAL INFLAMMATIONS | + | *WO2018185347A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INTERNAL INFLAMMATIONS<br>The invention relates to a pharmaceutical composition based on an aqueous solution of chlorine dioxide adapted as a solution for rectal intestinal lavage, as a solution for ureteral and bladder lavage or as an isotonic injection or infusion solution for use in the systemic treatment of acute or chronic internal inflammations and clinically relevant symptoms or states of the human or animal organism brought about thereby. The composition contains 5 to 1000 mg/l (ppm) of dissolved chlorine dioxide (ClO2) and is in a ready-to-use state substantially free from chlorate ions, hydrochloric acid and gaseous chlorine or contains these components in a concentration of not more than 1 mg/L (1 ppm) in each case. |
− | The invention relates to a pharmaceutical composition based on an aqueous solution of chlorine dioxide adapted as a solution for rectal intestinal lavage, as a solution for ureteral and bladder lavage or as an isotonic injection or infusion solution for use in the systemic treatment of acute or chronic internal inflammations and clinically relevant symptoms or states of the human or animal organism brought about thereby. The composition contains 5 to 1000 mg/l (ppm) of dissolved chlorine dioxide (ClO2) and is in a ready-to-use state substantially free from chlorate ions, hydrochloric acid and gaseous chlorine or contains these components in a concentration of not more than 1 mg/L (1 ppm) in each case. | + | *WO2018185348A1<br>PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE INTOXICATION<br>The invention relates to a pharmaceutical composition based on a highly pure aqueous solution of chlorine dioxide for use in the local or systemic treatment of acute intoxication caused by toxic substances from plants, mushrooms, aquatic animals, amphibians, reptiles, spiders, or insects and the clinically relevant symptoms or conditions caused thereby of human or animal organisms. The composition contains 5 to 3000 mg/l (ppm) of dissolved chlorine dioxide (CI02) and is substantially free of chlorate ions, hydrochloric acid |
− | The invention relates to a pharmaceutical composition based on a highly pure aqueous solution of chlorine dioxide for use in the local or systemic treatment of acute intoxication caused by toxic substances from plants, mushrooms, aquatic animals, amphibians, reptiles, spiders, or insects and the clinically relevant symptoms or conditions caused thereby of human or animal organisms. The composition contains 5 to 3000 mg/l (ppm) of dissolved chlorine dioxide (CI02) and is substantially free of chlorate ions, hydrochloric acid | |